Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Rheumatic Diseases Clinics of North America|July 3, 2021
Treatment Update in Systemic Lupus ErythematousAlberta Y Hoi, Eric F MorandExpert Opinion on Biological Therapy|August 9, 2012
Abatacept in the treatment of lupusAlberta Y Hoi, Geoffrey O LittlejohnThe Journal of Rheumatology|January 17, 2017
Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge GapVera Golder, Eric F Morand, Alberta Y HoiImmunology and Cell Biology|September 13, 2003
Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?Alberta Y Hoi, Eric F Morand, Michelle LeechInflammation & Allergy Drug Targets|September 28, 2007
Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseasesAlberta Y Hoi, Magdy N Iskander, Eric F MorandLupus Science & Medicine|December 8, 2017
Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?Daniel Boulos, Rachel L Koelmeyer, Eric F Morand, et al.Immunity, Inflammation and Disease|May 7, 2021
Granulocyte colony-stimulating factor is not pathogenic in lupus nephritisTimothy A Gottschalk, Fabien B Vincent, Alberta Y Hoi, et al.Lupus Science & Medicine|June 18, 2020
Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosusFabien B Vincent, Rangi Kandane-Rathnayake, Rachel Koelmeyer, et al.Clinical & Translational Immunology|April 27, 2019
Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosusFabien B Vincent, Rangi Kandane-Rathnayake, Rachel Koelmeyer, et al.Lupus|July 31, 2026
Clinical phenotypes and disease outcomes of patients with systemic lupus erythematosus meeting indication for primary aldosteronism testingMatthew Wong, Muhammad Akram, Joanna R Kent, et al.Pageof 2